J Korean Neurosurg Soc.  2012 Dec;52(6):517-522. 10.3340/jkns.2012.52.6.517.

Long-Term Follow-Up Result of Hydroxyurea Chemotherapy for Recurrent Meningiomas

• Kim MS
• Yu DW
• Jung YJ
• Kim SW
• Chang CH
• Kim OL

• KMID: 1426260
• DOI: http://doi.org/10.3340/jkns.2012.52.6.517

Abstract

OBJECTIVE
Meningiomas represent 18-20% of all intracranial tumors and have a 20-50% 10-year recurrence rate, despite aggressive surgery and irradiation. Hydroxyurea, an inhibitor of ribonucleotide reductase, is known to inhibit meningioma cells by induction of apoptosis. We report the long-term follow-up result of hydroxyurea therapy in the patients with recurrent meningiomas.
METHODS
Thirteen patients with recurrent WHO grade I or II meningioma were treated with hydroxyurea (1000 mg/m2/day orally divided twice per day) from June 1998 to February 2012. Nine female and 4 male, ranging in age from 32 to 83 years (median age 61.7 years), were included. Follow-up assessment included physical examination, computed tomography, and magnetic resonance imaging (MRI). Standard neuro-oncological response criteria (Macdonald criteria) were used to evaluate the follow-up MRI scans. The treatment was continued until there was objective disease progression or onset of unmanageable toxicity.
RESULTS
Ten of the 13 patients (76.9%) showed stable disease after treatment, with time to progression ranging from 8 to 128 months (median 72.4 months; 6 patients still accruing time). However, there was no complete response or partial response in any patients. Three patients had progressive disease after 88, 89, 36 months, respectively. There was no severe (Grade III-IV) blood systemic disorders and no episodes of non-hematological side effects.
CONCLUSION
This study showed that hydroxyurea is a modestly active agent against recurrent meningiomas and can induce long-term stabilization of disease in some patients. We think that hydroxyurea treatment is well tolerated and convenient, and could be considered as an alternative treatment option in patients with recurrent meningiomas prior to reoperation or radiotherapy.

Keyword

Meningioma; Chemotherapy; Hydroxyurea; Recurrence

MeSH Terms

Apoptosis
Disease Progression
Female
Follow-Up Studies
Humans
Hydroxyurea
Magnetic Resonance Imaging
Male
Meningioma
Physical Examination
Recurrence
Reoperation
Ribonucleotide Reductases
Hydroxyurea
Ribonucleotide Reductases

Figure

• 

  Fig. 1 Axial T1-weighted gadolinium-enhanced magnetic resonance (MR) images of patient 8 in Table 1, 2. A : Preoperative MR image demonstrating an enhancing mass lesion at the petrous apex with brainstem compression. B : Postoperative MR image demonstrating a remained mass lesion at petrous apex. C : MR image at 42 months after the operation demonstrating increased the mass. Hydroxyurea was started. After then, the tumor had been a stable disease. D : MR image at 89 months after initiation of hydroxyurea treatment demonstrating more increase the tumor and midbrain was compressed by tumor mass.

Reference

1. Adegbite AB, Khan MI, Paine KW, Tan LK. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg. 1983; 58:51–56. PMID: 6847909.

2. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy : brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975; 195:73–83. PMID: 810575.

3. Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996; 84:733–736. PMID: 8622144.

4. Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008; 113:2146–2151. PMID: 18756531.

5. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma : salvage therapy with long-acting somatostatin analogue. Neurology. 2007; 69:969–973. PMID: 17785665.

6. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma : a retrospective case series. J Neurooncol. 2011; 104:765–771. PMID: 21318318.

7. Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL. Benign meningiomas : primary treatment selection affects survival. Int J Radiat Oncol Biol Phys. 1997; 39:427–436. PMID: 9308947.

8. Forbes AR, Goldberg ID. Radiation therapy in the treatment of meningioma : the Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol. 1984; 2:1139–1143. PMID: 6491698.

9. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994; 80:195–201. PMID: 8283256.

10. Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet. 1998; 34:347–358. PMID: 9592619.

11. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG. Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma : results of a pilot study. J Neurooncol. 2005; 74:157–165. PMID: 16193387.

12. Kaba SE, DeMonte F, Bruner JM, Kyritsis AP, Jaeckle KA, Levin V, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery. 1997; 40:271–275. PMID: 9007858.

13. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery. 1992; 31:2–12. PMID: 1641106.

14. Kyritsis AP. Chemotherapy for meningiomas. J Neurooncol. 1996; 29:269–272. PMID: 8858533.

15. Lee JH, Kim OL, Kim SH, Bae JH, Choi BY, Cho SH. Hydroxyurea treatment for unresectable and uecurrent meningiomas. J Korean Neurosurg Soc. 2001; 30:S120–S123.

16. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD. Epidemiology of intracranial meningioma. Cancer. 1993; 72:639–648. PMID: 8334619.

17. Lori F, Lisziewicz J. Hydroxyurea : overview of clinical data and antiretroviral and immunomodulatory effects. Antivir Ther. 1999; 4(Suppl 3):101–108. PMID: 16021881.

18. Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004; 67:221–226. PMID: 15072471.

19. Martin DS, Stolfi RL, Colofiore JR. Perspective : the chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest. 1997; 15:372–381. PMID: 9246161.

20. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002; 97:341–346. PMID: 12186462.

21. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996; 34:817–822. PMID: 8598358.

22. Miralbell R, Linggood RM, de la Monte S, Convery K, Munzenrider JE, Mirimanoff RO. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol. 1992; 13:157–164. PMID: 1432033.

23. Navarra P, Preziosi P. Hydroxyurea : new insights on an old drug. Crit Rev Oncol Hematol. 1999; 29:249–255. PMID: 10226728.

24. Newton HB. Handbook of brain tumor chemotherapy. 2006. Amsterdam, Boston: Elsevier Medical Publishers/Academic Press;p. xvip. 510–524.

25. Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas : enlarged cohort with extended follow-up. Br J Neurosurg. 2004; 18:495–499. PMID: 15799152.

26. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol. 2000; 49:165–170. PMID: 11206012.

27. Newton HB, Turowski RC, Stroup TJ, McCoy LK. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother. 1999; 33:816–832. PMID: 10466912.

28. Noiri E, Masaki I, Fujino K, Tsuchiya M. Efficacy of a continuous syringe extraction method for monitoring hemodialysis ultrafiltrate. ASAIO J. 2000; 46:461–463. PMID: 10926147.

29. Pollock BE, Stafford SL, Utter A, Giannini C, Schreiner SA. Stereotactic radiosurgery provides equivalent tumor control to Simpson Grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys. 2003; 55:1000–1005. PMID: 12605979.

30. Rohringer M, Sutherland GR, Louw DF, Sima AA. Incidence and clinicopathological features of meningioma. J Neurosurg. 1989; 71:665–672. PMID: 2809720.

31. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002; 9:156–158. PMID: 11922703.

32. Schrell UM, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997; 86:845–852. PMID: 9126901.

33. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997; 86:840–844. PMID: 9126900.

34. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20:22–39. PMID: 13406590.

35. Stearns B, Losee KA, Bernstein J. Hydroxyurea. A new type of potential antitumor agent. J Med Chem. 1963; 6:201. PMID: 14188794.

36. Stewart BW. Mechanisms of apoptosis : integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst. 1994; 86:1286–1296. PMID: 8064887.